6533b7d9fe1ef96bd126c108
RESEARCH PRODUCT
Control de la dislipemia en grupos clínicos especiales: mujeres, ancianos, VIH, enfermedad renal crónica, pacientes con síndrome metabólico
Enrique RodillaJoaquín CardonaJose Maria Pascualsubject
medicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationHuman immunodeficiency virus (HIV)medicine.disease_causemedicine.diseaseInternal medicineJUPITER trialPrimary preventionmedicineRosuvastatinMetabolic syndromeCardiology and Cardiovascular MedicinebusinesseducationDyslipidemiamedicine.drugKidney diseasedescription
There is still some disagreement about how dyslipidemia should be treated in particular population groups. This article provides a review of indications for lipid-lowering treatment, preferably for primary prevention, in specific groups of patients: women, the elderly, and those with an HIV infection, chronic kidney disease or metabolic syndrome. Special emphasis is placed on data obtained in the JUPITER trial and in other studies of rosuvastatin.
year | journal | country | edition | language |
---|---|---|---|---|
2011-01-01 | Revista Española de Cardiología Suplementos |